To date, monitoring the expression of BCR-ABL1 fusion gene by q-PCR and identifying ABL kinase mutations by sequencing have been employed as effective means to predict disease relapse and resistance in CML and ALL patients. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.